Amit Patel - ImpediMed Non-Executive Director

IPDQF Stock  USD 0.06  0.02  26.75%   

Director

Mr. Amit Patel is NonExecutive Director of the Company. Mr Patel is an expert in digital health, with a depth of experience in commercializing technologies across the software and healthcare industries. He is currently the CEO and CoFounder of Vios Medical, which has developed an FDA cleared Internet of Things based patient management platform used across major hospitals in the US and India. He has held a number of senior roles in healthcare and medtech companies, including Medtronic. Mr Patel holds an MBA from Stanford University Graduate School of Business and a Bachelor of Biomedical Engineering from University of Minnesota Twin Cities. since 2017.
Tenure 7 years
Professional MarksMBA
Phone61 7 3860 3700
Webhttps://www.impedimed.com

ImpediMed Management Efficiency

The company has return on total asset (ROA) of (0.2848) % which means that it has lost $0.2848 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5192) %, meaning that it generated substantial loss on money invested by shareholders. ImpediMed's management efficiency ratios could be used to measure how well ImpediMed manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 170 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. ImpediMed Limited has a current ratio of 6.31, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ImpediMed until it has trouble settling it off, either with new capital or with free cash flow. So, ImpediMed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImpediMed Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImpediMed to invest in growth at high rates of return. When we think about ImpediMed's use of debt, we should always consider it together with cash and equity.
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people. ImpediMed Limited [IPDQF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

ImpediMed Limited Leadership Team

Elected by the shareholders, the ImpediMed's board of directors comprises two types of representatives: ImpediMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImpediMed. The board's role is to monitor ImpediMed's management team and ensure that shareholders' interests are well served. ImpediMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImpediMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
David BS, Ex Director
Michael Schreiber, VP of Global Commercialization
Timothy Cruickshank, Chief Officer
Leanne Ralph, Company Secretary
Michael Panaccio, Independent Non-Executive Director
Shashi Tripathi, CTO COO
Walton Taylor, Medical Director
Scott Ward, Director
Ann Holder, Senior Vice President - General Management & Operations
AAICD ACIS, Company Sec
Judith Downes, Non-Executive Director
Donald Williams, Non-Executive Director
Elizabeth Gaines, Non-Executive Director
Dennis Schlaht, VP Technology
Cherrell Hirst, Non-Executive Chairman of the Board
Thomas Schenk, Chief Officer
Catherine Kingsford, VP Affairs
Morten Vigeland, CFO
David Adams, Director
Frank Vicini, Chief Medical Officer
Nancy Deisinger, VP HR
Amit Patel, Non-Executive Director
Jack Cosentino, Chief Strategy Officer
Richard Carreon, CEO and President Managing Director and Executive Director
Michael Bassett, Sr Officer
Robert Graham, Non-Executive Director
Richard Valencia, MD CEO
Gary Goetzke, Non-Executive Director
James Hazel, Independent Non-Executive Director

ImpediMed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImpediMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImpediMed Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for ImpediMed Pink Sheet analysis

When running ImpediMed's price analysis, check to measure ImpediMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImpediMed is operating at the current time. Most of ImpediMed's value examination focuses on studying past and present price action to predict the probability of ImpediMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImpediMed's price. Additionally, you may evaluate how the addition of ImpediMed to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stocks Directory
Find actively traded stocks across global markets
Please note, there is a significant difference between ImpediMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImpediMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImpediMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.